Lynn E Heasley Selected Research

Lung Neoplasms (Lung Cancer)

5/2021	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer.
1/2021	TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin.
1/2020	Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
1/2019	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.
2/2018	ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.
1/2018	A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
1/2017	EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.
1/2017	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
1/2017	The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
12/2015	Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lynn E Heasley Research Topics

Disease

35	Neoplasms (Cancer) 01/2022 - 09/2002
20	Lung Neoplasms (Lung Cancer) 05/2021 - 10/2002
14	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 09/2006
10	Squamous Cell Carcinoma of Head and Neck 01/2022 - 08/2011
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 09/2002
3	Squamous Cell Neoplasms (Squamous Cell Cancer) 12/2019 - 10/2015
3	Carcinogenesis 03/2011 - 04/2006
2	Malignant Mesothelioma 01/2020 - 10/2014
2	Mesothelioma 01/2020 - 10/2014
2	Adenocarcinoma of Lung 01/2020 - 01/2018
2	Carcinoma (Carcinomatosis) 01/2018 - 10/2002
2	Leukemia 12/2015 - 04/2013
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2013 - 04/2013
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Liposarcoma 01/2021
1	Lewis Lung Carcinoma 01/2020
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2018
1	Inflammation (Inflammations) 01/2018
1	Pneumonia (Pneumonitis) 01/2018
1	Hepatitis 01/2018
1	Exanthema (Rash) 01/2018
1	Residual Neoplasm 01/2017
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2015
1	Triple Negative Breast Neoplasms 01/2015
1	Hypoxia (Hypoxemia) 09/2014
1	Adenocarcinoma 06/2014
1	Infections 10/2013
1	Neoplasm Metastasis (Metastasis) 10/2013
1	Pathologic Processes 01/2013

Drug/Important Bio-Agent (IBA)

12	Tyrosine Kinase InhibitorsIBA 05/2021 - 01/2009
10	Phosphotransferases (Kinase)IBA 12/2019 - 04/2006
9	Messenger RNA (mRNA)IBA 01/2019 - 08/2011
9	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 01/2009
8	Proteins (Proteins, Gene)FDA Link 01/2018 - 05/2005
6	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2013
6	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2009
6	ponatinibIBA 01/2019 - 06/2014
4	Pharmaceutical PreparationsIBA 01/2022 - 09/2014
4	Gefitinib (Iressa)FDA Link 01/2021 - 01/2009
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2019 - 05/2005
4	LigandsIBA 01/2017 - 01/2009
3	Cetuximab (Erbitux)FDA Link 01/2021 - 01/2015
3	CrizotinibIBA 02/2018 - 03/2012
3	tyrosine receptor (receptor, tyrosine)IBA 01/2018 - 04/2013
3	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 07/2015 - 01/2009
3	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 07/2015 - 08/2011
3	PPAR gammaIBA 03/2008 - 11/2002
2	CarcinogensIBA 01/2022 - 03/2011
2	InterferonsIBA 05/2021 - 01/2021
2	Biological ProductsIBA 01/2021 - 01/2013
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 12/2019
2	AsbestosIBA 01/2020 - 10/2014
2	B7-H1 AntigenIBA 01/2020 - 01/2017
2	Protein Kinases (Protein Kinase)IBA 12/2019 - 10/2015
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2019 - 08/2011
2	Mitogen-Activated Protein KinasesIBA 12/2019 - 09/2002
2	SilverIBA 01/2019 - 07/2015
2	AZD4547IBA 01/2018 - 10/2015
2	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 09/2002
2	Small Interfering RNA (siRNA)IBA 01/2017 - 04/2013
2	Cadherins (E-Cadherin)IBA 01/2017 - 05/2005
2	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 07/2015 - 10/2013
2	FP-1039IBA 10/2014 - 08/2011
2	Transcription Factors (Transcription Factor)IBA 09/2014 - 09/2002
2	JNK Mitogen-Activated Protein KinasesIBA 05/2010 - 09/2002
2	gamma Catenin (Plakoglobin)IBA 05/2004 - 10/2002
1	EphB4 ReceptorIBA 01/2022
1	osimertinibIBA 05/2021
1	AZD 8931IBA 01/2021
1	eribulin FDA Link 01/2021
1	liquid crystal polymerIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2020
1	Interferon-gamma (Interferon, gamma)IBA 01/2020
1	Sirolimus (Rapamycin)FDA Link 12/2019
1	Anaplastic Lymphoma KinaseIBA 02/2018
1	CytokinesIBA 01/2018
1	ChemokinesIBA 01/2018
1	MicroRNAs (MicroRNA)IBA 01/2018
1	Interferon Type IIBA 01/2018
1	Immune Checkpoint InhibitorsIBA 01/2017
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2017
1	(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA 12/2015
1	MTOR InhibitorsIBA 10/2015
1	vistusertibIBA 10/2015
1	infigratinibIBA 10/2015
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2015
1	Monoclonal AntibodiesIBA 01/2015
1	1-methyl-1-piperidinomethane sulfonateIBA 10/2014
1	Pyruvate Dehydrogenase Acetyl-Transferring KinaseIBA 09/2014
1	bosutinibIBA 09/2014
1	Formaldehyde (Formol)FDA Link 10/2013
1	Nicotine FDA Link 10/2013
1	ParaffinIBA 10/2013
1	Proto-Oncogene Proteins c-metIBA 04/2013
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2013

Therapy/Procedure

20	Therapeutics 01/2022 - 04/2006
4	Immunotherapy 01/2020 - 01/2017
2	Precision Medicine 01/2018 - 09/2014
1	Drug Therapy (Chemotherapy) 12/2019